Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Impact of biologic and JAK inhibitor therapy on aortic stiffness and carotid intima-media thickness in ulcerative colitis
2020-004391-18Phase 4Active
- Sponsor
- CHU Amiens-Picardie
- Start
- Sep 2020
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4 trial of infliximab, adalimumab, golimumab, vedolizumab and tofacitinib in autoimmune colitis (5 arms), sponsored by CHU Amiens-Picardie. Primary endpoint: Carotid intima media thickness (CIMT). Started Sep 2020; status: active.
02
Drugs
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2020-004391-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-004391-18.